Table 1 Patient characteristics - retrospective chart review
From: Optimal treatment of opioid induced constipation in daily clinical practice – an observational study
Total N = 327 (%) | Fentanyl Maintenance N = 131 (%) | Oxycodon maintenance N = 90 (%) | P (fentanyl vs. oxycodone) | ||
|---|---|---|---|---|---|
Age | mean (SD) | 63 (12) | 64 (11) | 63 (12) | 0,368 |
Sex | Male | 146 (45) | 64 (49) | 41 (46) | |
Female | 181 (55) | 67 (51) | 49 (54) | 0,629 | |
Cancer type | Gastro-intestinal | 110 (34) | 43 (33) | 26 (29) | |
Breast | 54 (17) | 13 (10) | 19 (21) | ||
Genito-urethral | 62 (19) | 23 (20) | 26 (29) | ||
Skin | 15 (5) | 7 (5) | 5 (6) | ||
Lung | 1 (0) | 1 (1) | 0 (0) | ||
Head&Neck | 53 (16) | 33 (25) | 5 (6) | ||
Brain | 3 (1) | 1 (1) | 0 (0) | ||
Sarcoma | 6 (2) | 2 (2) | 2 (2) | ||
Other | 23 (7) | 5 (4) | 7 (8) | 0,005* | |
Treatment intention | Curative | 71 (22) | 37 (28) | 9 (10) | |
Palliative | 256 (78) | 94 (72) | 81 (90) | 0,001* | |
Current Treatment | Follow-up | 7 (2) | 3 (2) | 1 (1) | |
Watchfull waiting | 22 (7) | 7 (5) | 5 (6) | ||
Chemotherapy | 90 (28) | 32 (24) | 28 (31) | ||
Radiotherapy | 15 (5) | 7 (5) | 5 (6) | ||
Chemoradiotherapy | 38 (12) | 25 (19) | 3 (3) | ||
Targetted therapy | 51 (16) | 17 (13) | 17 (19) | ||
Best supportive care | 81 (25) | 33 (25) | 24 (27) | ||
Other | 23 (7) | 7 (5) | 7 (8) | 0,032* | |
ECOG performance status | 0 | 14 (4) | 3 (2) | 7 (8) | |
1 | 110 (34) | 40 (31) | 36 (40) | ||
2 | 67 (21) | 22 (17) | 20 (22) | ||
3 | 29 (9) | 14 (11) | 11 (12) | ||
4 | 17 (5) | 6 (5) | 1 (1) | ||
Unknown | 90 (28) | 46 (35) | 15 (17) | 0,264 | |
Contributing factors | Peritoneal tumor depositions | 52 (16) | 21 (16) | 13 (14) | 0,748 |
Intestinal metastasis | 19 (6) | 8 (6) | 3 (3) | 0,352 | |
Involvement of other abdominal organs | 115 (35) | 45 (34) | 34 (38) | 0,602 | |
Hypercalcemia | 21 (6) | 13 (10) | 6 (7) | 0,239 | |
Reduced mobility | 116 (36) | 47 (36) | 34 (38) | 0,773 | |
Intake failure | 71 (22) | 41 (31) | 9 (10) | < 0,001* | |
Constipating co-medication | 75 (23) | 30 (23) | 18 (20) | 0,607 | |
Abdominal innervation problems | 11 (3) | 1 (1) | 7 (8) | 0,006* | |
Bowel disease | 4 (1) | 1 (1) | 1 (1) | 0,789 | |
Depression | 3 (1) | 2 (2) | 0 (0) | 0,239 | |
Pain Scorea | NRS 0–10, mean (SD) | 4,0 (6,0) | 4,0 (5,0) | 5,0 (6,5) | 0,948 |
Opioid dosesb | Maintenance dose, median (IQR) | 60 (29–120) | 60 (29–120) | 40 (40–80) | 0,006* |
Rescue dosec | 20 (3–40) | 23 (10–50) | 20 (0–40) | 0,259 | |
Rescue opioid subtypes | No rescue opioid | 36 (11) | 9 (7) | 6 (7) | |
Buprenorfine | 14 (4) | 0 (0) | 0 (0) | ||
Fentanyl | 24 (7) | 17 (13) | 3 (3) | ||
Methadon | 2 (1) | 0 (0) | 0 (0) | ||
Morphine | 57 (17) | 34 (26) | 5 (6) | ||
Oxycodon | 185 (57) | 71 (54) | 76 (84) | ||
Tramadol | 5 (2) | 0 (0) | 0 (0) | ||
Other | 4 (1) | 0 (0) | 0 (0) | < 0,001* |